Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2, Issue 7
April 10 2018
Issue Cover

Table of Contents

POINT-COUNTERPOINT

Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?
Karl S. Peggs

This article has a companion Counterpoint by Moskowitz.

View Articletitled, Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?
Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily
Craig H. Moskowitz

This article has a companion Point by Peggs.

View Articletitled, Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily

CLINICAL TRIALS AND OBSERVATIONS

A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
Clinical Trials & Observations
Chaitra Ujjani,Hongkun Wang,Alan Skarbnik,Neel Trivedi,Pari Ramzi,Nadia Khan,Bruce D. Cheson
View Articletitled, A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation
Clinical Trials & Observations
M Hasib Sidiqi,Mohammed A. Aljama,Eli Muchtar,Francis K. Buadi,Rahma Warsame,Martha Q. Lacy,Angela Dispenzieri,David Dingli,Nelson Leung,Wilson I. Gonsalves,Shaji K. Kumar,Prashant Kapoor,Taxiarchis V. Kourelis,William J. Hogan,Morie A. Gertz
View Articletitled, Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation
Supplemental data

LYMPHOID NEOPLASIA

Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma
Clinical Trials & Observations
Marie-Hélène Delfau-Larue,Axel van der Gucht,Jehan Dupuis,Jean-Philippe Jais,Isabelle Nel,Asma Beldi-Ferchiou,Salma Hamdane,Ichrafe Benmaad,Gaelle Laboure,Benjamin Verret,Corinne Haioun,Christiane Copie-Bergman,Alina Berriolo-Riedinger,Philippine Robert,René-Olivier Casasnovas,Emmanuel Itti
View Articletitled, Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma
Supplemental data

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

Selectins and chemokines use shared and distinct signals to activate β2 integrins in neutrophils
Tadayuki Yago,Nan Zhang,Liang Zhao,Charles S. Abrams,Rodger P. McEver
View Articletitled, Selectins and chemokines use shared and distinct signals to activate β2 integrins in neutrophils
Supplemental data

PLATELETS AND THROMBOPOIESIS

2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia
Elizabeth Tkaczynski,Abinaya Arulselvan,John Tkaczynski,Stephen Avery,Liqing Xiao,Beverly Torok-Storb,Kraig Abrams,Narayanam V. Rao,Gregory Johnson,Thomas P. Kennedy,Mortimer Poncz,Michele P. Lambert
View Articletitled, 2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia
Supplemental data
Defective RAB1B-related megakaryocytic ER-to-Golgi transport in RUNX1 haplodeficiency: impact on von Willebrand factor
Gauthami Jalagadugula,Lawrence E. Goldfinger,Guangfen Mao,Michele P. Lambert,A. Koneti Rao
View Articletitled, Defective RAB1B-related megakaryocytic ER-to-Golgi transport in RUNX1 haplodeficiency: impact on von Willebrand factor
Supplemental data

THROMBOSIS AND HEMOSTASIS

Risk of recurrent venous thromboembolism according to baseline risk factor profiles
Clinical Trials & Observations
Martin H. Prins,Anthonie W. A. Lensing,Paolo Prandoni,Philip S. Wells,Peter Verhamme,Jan Beyer-Westendorf,Rupert Bauersachs,Henri Bounameaux,Timothy A. Brighton,Alexander T. Cohen,Bruce L. Davidson,Hervé Decousus,Ajay K. Kakkar,Bonno van Bellen,Akos F. Pap,Martin Homering,Miriam Tamm,Jeffrey I. Weitz
View Articletitled, Risk of recurrent venous thromboembolism according to baseline risk factor profiles
Supplemental data

TRANSPLANTATION

Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity
Clinical Trials & Observations
Zachariah DeFilipp,Jonathan U. Peled,Shuli Li,Jasmin Mahabamunuge,Zeina Dagher,Ann E. Slingerland,Candice Del Rio,Betsy Valles,Maria E. Kempner,Melissa Smith,Jami Brown,Bimalangshu R. Dey,Areej El-Jawahri,Steven L. McAfee,Thomas R. Spitzer,Karen K. Ballen,Anthony D. Sung,Tara E. Dalton,Julia A. Messina,Katja Dettmer,Gerhard Liebisch,Peter Oefner,Ying Taur,Eric G. Pamer,Ernst Holler,Michael K. Mansour,Marcel R. M. van den Brink,Elizabeth Hohmann,Robert R. Jenq,Yi-Bin Chen
View Articletitled, Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity
Supplemental data
Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis
Clinical Trials & Observations
Juliana M. F. Silva,Fani Ladomenou,Ben Carpenter,Sharat Chandra,Petr Sedlacek,Renata Formankova,Vicky Grandage,Mark Friswell,Andrew J. Cant,Zohreh Nademi,Mary A. Slatter,Andrew R. Gennery,Sophie Hambleton,Terence J. Flood,Giovanna Lucchini,Robert Chiesa,Kanchan Rao,Persis J. Amrolia,Paul Brogan,Lucy R. Wedderburn,Julie M. Glanville,Rachael Hough,Rebecca Marsh,Mario Abinun,Paul Veys
View Articletitled, Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis

ERRATUM

Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018;2(4):444-453.
View Articletitled, Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <em>Blood Adv</em>. 2018;2(4):444-453.
  • Cover Image

    Cover Image

    issue cover

    COVER FIGURE
    During inflammation, neutrophils rolling in venules integrate signals from selectins and chemokines to induce β2 integrin–dependent slow rolling and arrest. Cooperative signaling activates both Rap1a and PIP5Kγ90 to recruit talin-1. See the article by Yago et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

American Society of Hematology: Building a Comprehensive Minority Recruitment and Retention Professional Program
Model-based dosing for better survival after transplantation
Lezina L, Spriggs RV, Beck D, et al. CD40L/IL-4–stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM. Blood Adv. 2018;2(15):1869-1881.
Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease
Adeno-associated virus–based gene therapy for hemophilia A and B: a systematic review and meta-analysis

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals